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CRC incidence, mortality, recurrence rates, harm parameters, and screening participation rates.
Modelling
A state transition model, which consisted of three interlinked sub-models, was developed. The three models simulated: the natural history of CRC; screening and subsequent surveillance -which interacts directly with the natural history; and mortality, including age-specific, other cause, CRC-related, and perforation due to endoscopic procedures.
Full details of the model and their interactions were presented in the paper. In addition, a supplementary appendix was made available (http://gut.bmj.com/supplemental).
Sources searched to identify primary studies
The clinical effectiveness data were derived from published studies. Whist it is apparent from the reporting that a number of UK sources had been used, the details of individual trials were not presented.
Methods used to judge relevance and validity, and for extracting data
The methods used to identify and select the data used to populate the model were not reported. No inclusion criteria were specified for any of the parameters.
Measure of benefits used in the economic analysis
The measures of benefit used were the life-years gained (LYGs) and the quality-adjusted life-years (QALYs). The utility weights were derived from a published study. The benefits were discounted at a rate of 3.5%.
Direct costs
The study considered two groups of costs, those associated with the screening programme and those associated with the diagnosis, treatment and follow-up of CRC. The resource quantities were reported separately from the unit costs. The resource data were obtained from the literature and expert opinion. The price data were obtained from the NHS Reference Costs, from published studies and from clinical expert opinion. The costs were discounted at an annual rate of 3.5%. The price year appears to have been 2003.
Statistical analysis of costs
The quantities and costs were treated stochastically.
Indirect Costs
Inline with the perspective adopted, no productivity losses were included.
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Sensitivity analysis
Variability in the data was explored. A one-way sensitivity analysis was undertaken to explore the impact of changing individual values for cost and participation parameters on central estimates of cost-effectiveness. A probabilistic sensitivity analysis was carried out to evaluate parameter uncertainty. Each variable was assigned a distribution and Monte Carlo simulations were performed.
Estimated benefits used in the economic analysis
The incremental LYGs for the five screening strategies versus the no screening option were 0.026 for biennial FOBT at age 50 -69 years, 0.0126 biennial FOBT at age 60 -69 years, 0.0237 for FSIG once at age 55 years, 0.0197 for FSIG once at age 60 years, and 0.0271 for FSIG once at age 60 years and biennial FOBT at age 61 -70 years.
The incremental QALYs of screening versus no screening were 0.0227 for biennial FOBT at age 50 -69 years, 0.0104 for biennial FOBT at age 60 -69 years, 0.027 for FSIG once at age 55 years, 0.0221 for FSIG once at age 60 years, and 0.0282 for FSIG once at age 60 years and biennial FOBT at age 61 -70 years.
Cost results
The marginal cost of the five screening strategies versus the no screening option was 66.95 for biennial FOBT at age 50 -69 years, 24.53 for biennial FOBT at age 60 -69 years, -28.77 for FSIG once at age 55 years, -28.51 for FSIG once at age 60 years, and -1.92 for FSIG once at age 60 years and biennial FOBT at age 61 -70 years.
Synthesis of costs and benefits
The incremental cost per LYG for screening versus no screening was 2,576.72 for biennial FOBT at age 50 -69 years and 1,950.29 for biennial FOBT at age 60 -69 years.
The incremental cost per QALY for screening versus no screening was 2,949.64 for biennial FOBT at age 50 -69 years and 2,364.99 for biennial FOBT at age 60 -69 years.
FSIG once at age 55 years, FSIG once at age 60 years, and FSIG once at age 60 years followed by biennial FOBT at age 61 to 70 years were dominant.
The one-way sensitivity analysis showed that the greatest impact on cost-utility resulted from the use of alternative series of calibrated transition probabilities. The incremental cost per QALY for the best and worst sets ranged from 551 to 7,992 for biennial FOBT at age 50 -69 years and from 15 to 6,111 for biennial FOBT at age 60 -69 years. The probabilistic sensitivity analysis using a marginal cost-effectiveness plane showed that all of the screening options would appear to be economically attractive in comparison with a policy of no screening. FSIG offered to individuals aged between 50 and 60 could always be expected to dominate the no screening option, while FOBT at age 60 -69 years could always be expected to be more expensive and less effective than the once-only FSIG option.
Authors' conclusions
Screening using faecal occult blood testing (FOBT) and/or flexible sigmoidoscopy (FSIG) is a potentially cost-effective strategy for the early detection of colorectal cancer (CRC).
CRD COMMENTARY -Selection of comparators
The rationale for the choice of the comparator was clear in that it represented standard practice for CRC screening in the UK. You should decide whether this represents current practice in your own setting.
